HIF1A and sarcoma: There are several HIF-1α inhibitors that are in various phases of clinical development; however, none are approved for clinical use.48 Although Dox clearly has effects other than inhibiting HIF-1α, the primary advantage of using metronomic Dox in our study is that Dox is already clinically approved for the treatment of sarcomas and that findings from our study can be immediately translated into clinical trials combining metronomic Dox with VEGF inhibitors such as bevacizumab.